Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
- Author(s)
- Delbridge, AR; Grabow, S; Strasser, A; Vaux, DL;
- Details
- Publication Year 2016-01-29,Volume 16,Issue #2,Page 99-109
- Journal Title
- Nature Reviews Cancer
- Publication Type
- Journal Article
- Abstract
- The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies. Over the past 30 years, research on the BCL-2-regulated apoptotic pathway has led to the development of small-molecule compounds, known as 'BH3-mimetics', that bind to pro-survival BCL-2 proteins to directly activate apoptosis of malignant cells. This Timeline article focuses on the discovery and study of BCL-2, the wider BCL-2 protein family and, specifically, its roles in cancer development and therapy.
- Publisher
- NPG
- Research Division(s)
- Cell Signalling And Cell Death; Molecular Genetics Of Cancer
- PubMed ID
- 26822577
- Publisher's Version
- https://doi.org/10.1038/nrc.2015.17
- NHMRC Grants
- NHMRC/1020363, NHMRC/1020136,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2016-03-14 03:05:29
Last Modified: 2018-03-26 02:40:45